Therapeutic observations in MCF-7 aromatase xenografts

Clinical Cancer Research

Volumn 11, Issue 2 II, 2005, Pages

  Brodie, Angela ^a   Jelovac, Danijela ^a   Macedo, Luciana ^a   Sabnis, Gauri ^a   Tilghman, Syreeta ^a   Goloubeva, Olga ^a   Osborne, Kent ^b   Santen, Richard ^b   Johnston, Stephen ^b   Yee, Douglas ^b   Lønning, Per ^b   Ingle, James ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; EXEMESTANE; FULVESTRANT; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; RAF PROTEIN; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HORMONAL REGULATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE; AROMATASE INHIBITORS; DISEASE MODELS, ANIMAL; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NITRILES; RECEPTORS, ESTROGEN; TRIAZOLES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 19944426356     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Zhou D, Pompon D, Chen S. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 1990;50:6949-54.
2. Yue W, Zhou DJ, Chen S, Brodie AMH. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 1994;54:5092-5.
3. Yue W, Wang J, Savinov A, Brodie A. Effect of aromatase inhibitors on the growth of mammary tumors in a nude mouse model. Cancer Res 1995;55:3073-7.
4. Lu Q, Wang J, Liu Y, Long B, Brodie A. The effects of aromatase and antiestrogens in the nude mouse model. Breast Cancer Res Treat 1998;50:63-71.
5. Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie A. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 1999;57:183-92.
6. Miller WR, Forrest APM. Oestradiol synthesis by a human breast carcinoma. Lancet 1974;2:866-8.
7. Lu Q, Nakamura J, Savinov A, et al. Expression of aromatase protein and mRNA in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancer. Endocrinology 1996;137:3061-8.
8. Long BJ, Jelovac D, Handratta V, et al. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in breast cancer model. J Natl Cancer Inst 2004;96:456-65.
9. Jelovac D, Macedo L, Handratta V, Long BJ, Goloubeva OG, Brodie AMH. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. In press.
10. Jelovac D, Goloubeva OG, Handrotta V, et al. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. In Press.
11. Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359:2131-9.
12. Zaccheo T, Giudici D, Di Salle E. Inhibitory effects of combining treatment with aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats. J Steroid Biochem Mol Biol 1993;44:677-80.
13. Dowsett M, Haynes BP. Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol 2003;86:255-63.
14. Hutson PR, Love RR, Cleary JF, Kim K. Pharmacokinetic and pharmacodynamic interaction of adjuvant tamoxifen and exemestane in postmenopausal women treated for early stage breast cancer (abstract 260). Breast Cancer Res Treat 2002;76:S74.
15. Rivera E, Valero V, Francis D, Hortobagyi G. Pharmacokinetic (PK) study to evaluate the combination of exemestane (E) and tamoxifen (T) in the treatment of metastatic breast cancer: preliminary results (abstract 261). Breast Cancer Res Treat 2002;76:S75.
16. Jelovac D, Long B, Brodie A. Overexpression of Grb2 in MCF-7Ca mammary tumors proliferating during letrozole treatment of nude mice. 95th Annual Meeting of AACR; 2004.
17. Long BJ, Jelovac D, Thiantanawat A, Brodie AM. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin Cancer Res 2002;8:2378-88.
18. Brodie AH, Jelovac D, Long B. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens. J Steroid Biochem Mol Biol 2003;86:283-8.